Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and lapatinib

erlotinib hydrochloride has been researched along with lapatinib in 95 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010) (lapatinib)
4,3537863,0331,9193051,442

Protein Interaction Comparison

ProteinTaxonomyerlotinib hydrochloride (IC50)lapatinib (IC50)
Bile salt export pumpHomo sapiens (human)7.375
Epidermal growth factor receptorHomo sapiens (human)0.0827
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0537
Platelet-derived growth factor receptor betaHomo sapiens (human)8.5
D(1A) dopamine receptorSus scrofa (pig)0.06
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)1
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.1659
Alpha-1A adrenergic receptor Sus scrofa (pig)0.06
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)3.2

Research

Studies (95)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's18 (18.95)29.6817
2010's70 (73.68)24.3611
2020's7 (7.37)2.80

Authors

AuthorsStudies
Bonomi, P1
Alligood, KJ; Dickerson, SH; Ellis, B; Gilmer, TM; Hassell, A; Horne, E; Lackey, K; McDonald, OB; Pennisi, C; Rusnak, DW; Shewchuk, L; Truesdale, AT; Wood, ER; Yuan, D1
Berlin, JD; Lockhart, AC; Lockhart, C1
Burtness, B1
Andersson, M; Nielsen, DL1
Campone, M; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Mayer, F1
Lacouture, ME; Mitchell, EP; Perez-Soler, R; Van Cutsem, E1
Giordano, S; Petrelli, A1
Avizienyte, E; Garner, AP; Ward, RA1
Agulnik, M; Wang, LX1
Loeffler-Ragg, J; Schwentner, I; Sprinzl, GM; Zwierzina, H1
Abidoye, O; Salgia, R; Sattler, M1
Anania, FA; Knight, BB; Merlin, D; O'Regan, RM; Saxena, NK; Sharma, D; Taliaferro-Smith, L1
Clynes, M; Collins, DM; Crown, J; Devery, A; O'Connor, R; O'Donovan, N; O'Driscoll, L; O'Sullivan, F1
Boronina, T; Cole, PA; Cole, RN; Kavran, JM; Leahy, DJ; Longo, PA; Qiu, C; Tarrant, MK1
Cohen, EE; Halpern, AB; Kasza, K; Kocherginsky, M; Vokes, EE; Williams, R1
Chen, X; Chen, ZS; Fu, LW; Hopper-Borge, E; Kuang, YH; Lee, JW; Shen, T; Sodani, K; Tiwari, AK1
Gelderblom, H; Guchelaar, HJ; van Erp, NP1
Banat, GA; Cornitescu, T; Dahal, BK; Dumitrascu, R; Ghofrani, HA; Grimminger, F; Kosanovic, D; Pullamsetti, SS; Schermuly, RT; Seeger, W; Tretyn, A; Voswinckel, R; Weissmann, N1
Carter, CA; Giaccone, G; Kelly, RJ1
Gutteridge, E; Robertson, JF1
Anghel, A; Ayala, R; Desai, AJ; Fejzo, MS; Finn, RS; Hecht, JR; Luo, T; Safran, B; Slamon, DJ; Wainberg, ZA1
Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y1
Gerami, P; Guitart, J; Lacouture, ME; Nardone, B; Newman, M; Nicholson, K; Rademaker, A; Talarico, N; West, DP; Yang, XJ1
Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N1
Anderson, A; Gilmer, TM; Greger, J; Liu, L; Liu, Y; Martin, AM; Peterson, J; Shi, H1
Beck, JF; Kurtze, I; Sonnemann, J1
Azria, D; Bascoul-Mollevi, C; Bazin, H; Chardès, T; Crapez, E; Gaborit, N; Larbouret, C; Mathis, G; Pèlegrin, A; Peyrusson, F; Poul, MA; Vallaghe, J1
Oberstein, PE; Saif, MW1
Dao-Pick, T; DeFazio-Eli, L; Goodman, L; Parry, G; Strommen, K; Winslow, J1
Anadkat, MJ; Balagula, Y; Lacouture, ME; Wu, PA1
Di Gion, P; Doroshyenko, O; Fuhr, U; Scheffler, M; Wolf, J1
Pandiella, A; Sánchez-Martín, M1
Cortes, J; Roché, H1
A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M1
Garden, BC; Lacouture, ME; Wu, S1
Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J1
Burns, SS; Bush, ML; Chang, LS; Davletova, S; Jacob, A; Oblinger, J; Welling, DB1
Lee, SH1
Azria, D; Bascoul-Mollevi, C; Campigna, E; Chardès, T; Coelho, M; Gaborit, N; Larbouret, C; Mach, JP; Pèlegrin, A; Robert, B1
Azuma, T; Fujishiro, Y; Matsuzaka, K; Ochiai, H; Tonogi, M; Yamane, GY1
Brennan, CW; Campos, C; Chang, SM; Chheda, MG; Cloughesy, TF; Dang, J; DeAngelis, LM; Drappatz, J; Fine, HA; Gilbert, MR; Grommes, C; Heguy, A; Horvath, S; Iwanami, A; Kubek, S; Kuga, D; Kuhn, JG; Lamborn, KR; Lassman, AB; Liau, LM; Lieberman, F; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nghiemphu, PL; Oldrini, B; Pedraza, A; Prados, MD; Reardon, DA; Robins, HI; Rohle, D; Tao, H; Vivanco, I; Wen, PY; Wu, N; Yannuzzi, N; Yong, WH; Yung, WK; Zhu, S1
Chen, Y; Han, B; Jia, J; Jiang, Y; Ma, X; Tan, C; Wei, X; Zhang, J; Zhu, F1
Bezler, M; Hengstler, JG; Ullrich, A1
Fujii, H; Jimmy So, A; Kono, K; Mimura, K; Shabbir, A; Yong, WP1
Corominas-Faja, B; Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Urruticoechea, A; Vazquez-Martin, A1
Hattori, S; Kage, M; Kan, H; Kawahara, A; Kuwano, M; Murakami, Y; Ono, M; Shibata, T; Ureshino, H; Watari, K1
Akhavan, D; Babic, I; Bensinger, SJ; Cavenee, WK; Cloughesy, TF; Dang, J; Flagg, M; James, CD; Kornblum, HI; Mischel, PS; Nael, A; Nathanson, D; Nourian, AA; Pourzia, AL; Sasayama, T; Tamanoi, F; Tanaka, K; Villa, GR; Vinters, HV; Williams, KJ; Yang, H; Yong, WH1
Andriamanana, I; Duretz, B; Gana, I; Hulin, A1
Balletta, L; Bridges, A; Cheang, MC; Combest, A; Darr, D; Herschkowitz, JI; Jordan, J; Karginova, O; Liu, M; Perou, CM; Prat, A; Roberts, PJ; Rosen, JM; Sharpless, NE; Usary, J; Zamboni, W; Zhao, W1
Baradia, D; Misra, A; Patil, S; Vhora, I; Yewale, C1
Adak, S; Landgraf, R; Macdonald-Obermann, JL; Pike, LJ; Piwnica-Worms, D1
Feddersen, CR; Fletcher, EV; Goel, A; Koch, AT; Love-Homan, L; Simons, AL; Sobhakumari, A1
Ashby, CR; Chen, ZS; Kathawala, RJ; Wang, YJ1
Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL1
Galichet, A; Müller, EJ; Rüegg, S; Sayar, BS; Schmidt, E; Sibilia, M; Siffert, M; Suter, MM1
Behera, R; Mensa-Wilmot, K; Thomas, SM1
Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O1
Crews, LA; Gonzales, T; Kouznetsova, VL; Masliah, E; Overk, CR; Patrick, C; Paulino, A; Price, D; Rockenstein, E; Stocking, E; Tsigelny, IF; Wrasidlo, W1
Annunziato, S; Benedicenti, F; Brasca, S; Calabria, A; Gallina, P; Montini, E; Naldini, L; Ranzani, M1
Brown, D; Butowski, N; Cheng, SY; Giles, FJ; James, CD; Mazar, AP; Nicolaides, T; Ozawa, T; Parsa, AT; Raizer, JJ; Sarkaria, JN; Shen, W; Stegh, AH; Yao, TW; Yoshida, Y1
Haskins, JW; Nguyen, DX; Stern, DF1
Anderson, JC; Arafat, W; Bonner, JA; Denton, AJ; Dobelbower, MC; Dussaq, AM; Gilbert, AN; Minnich, DJ; Rohrbach, TD; Welaya, K; Willey, CD1
Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L1
Chang, YH; Hong, SE; Hong, SI; Hong, YJ; Jin, HO; Kim, B; Kim, CS; Kim, JH; Kim, JY; Lee, JK; Park, IC; Park, JA1
Chen, WD; Deng, R; Feng, GK; Ji, J; Jiao, L; Kong, PF; Li, X; Li, YT; Li, ZH; Qian, XJ; Wu, RY; Yu, Y; Zhu, XF1
Cosmai, L; Gallieni, M; Porta, C1
Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H1
Bower, M; Erbacher, I; Fortunak, J; Gotham, D; Hill, A; Levi, J; Martin, M; Meldrum, J; Powderly, WG; Shoman, H1
Mehra, R; Zibelman, M1
Broutin, S; Gil, S; Jovelet, C; Mir, O; Paci, A1
Becker, C; Keul, M; Nguyen, HD; Öcal, S; Phan, T; Rauh, D; Simard, JR1
Li, G; Yang, B; Yang, N; Yang, YS; Zhu, HL1
Manole, S; Meyer, AS; Richards, EJ1
Griffith, N; Kolli, S; Li, Q; Liu, Z; Poi, MJ; Wetz, K1
Chang, TY; Chen, PS; Hsu, HP; Huang, MT; Kuo, KT; Lai, HH; Li, JN; Lyu, YJ; Su, CM; Su, JL1
Bando, H; Fujisawa, F; Hara, H; Homma, M; Kaburagi, T; Kojima, H; Mitsuhashi, S; Naito, K; Ohgami, M; Suzuki, Y; Takei, K; Uchiumi, K; Yamada, M; Yamada, Y1
Kannan, N; Katiyar, S; Ruan, Z1
Abahussain, AO; Alzoman, NZ; Maher, HM; Shehata, SM1
Antony, J; El-Bahrawy, M; Gabra, H; Karali, E; Louis, LS; McKie, AB; Okon, IS; Recchi, C; Stebbing, J; Vaughan, S; Zanini, E1
Cescon, D; El-Hachem, N; Haibe-Kains, B; Lupien, M; Mak, TW; Quevedo, R; Safikhani, Z; Silvester, J; Smirnov, P; Thu, KL1
Crabb, SJ; Douglas, J; Hayden, A; Markham, H; Mora Vidal, R; Packham, G; Regufe da Mota, S1
Bown, JL; Deeni, YY; Kankia, IH; Khalil, HS; Langdon, SP; Moult, PR1
Macdonald-Obermann, JL; Pike, LJ1
Dekker, H; Labots, M; Meijer, GA; Pham, TV; Ruijter, R; Van der Hoeven, JJM; Van der Mijn, JC; Van der Vliet, HJ; Verheul, HMW1
Ayanoglu, BT; Demirdag, HG; Yalici-Armagan, B1
Boswell, SA; Erickson, AR; Everley, RA; Haigis, MC; Holton, KM; Jacobson, CA; Maliszewski, L; Palmer, AC; Ringel, AE; Ron-Harel, N; Sheehan, RP; Sorger, PK; Wang, H1
Kim, HS; Kim, JY; Yoon, S1
Brors, B; Haibe-Kains, B; Kurilov, R1
Batchelder, E; Drabick, JJ; Lehrer, EJ; Machtay, M; Sharma, N; Tchelebi, LT; Trifiletti, DM; Wang, M; Zaorsky, NG1
Al-Zubaidi, Y; Bourget, K; Murray, M; Rahman, MK; Tam, S; Zhou, F1
Lucia, F; Nicolas, E1
Acconcia, F1
Feng, M; Li, Q; Liao, W; Qian, Z; Wen, F; Wu, Q; Yang, Y1
Tan, J; Xu, M; Zhong, Z1

Reviews

25 review(s) available for erlotinib hydrochloride and lapatinib

ArticleYear
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 1

    Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Organic Chemicals; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Treatment Outcome

2003
The epidermal growth factor receptor as a target for colorectal cancer therapy.
    Seminars in oncology, 2005, Volume: 32, Issue:1

    Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction

2005
Her signaling in pancreatic cancer.
    Expert opinion on biological therapy, 2007, Volume: 7, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Epidermal Growth Factor; Erlotinib Hydrochloride; Gemcitabine; Humans; Lapatinib; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome

2007
[Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
    Ugeskrift for laeger, 2007, Sep-10, Volume: 169, Issue:37

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Trastuzumab

2007
[Targeting ErbB receptors in breast cancer].
    Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab

2007
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:11 Suppl 5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Lapatinib; Nail Diseases; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Telangiectasis

2007
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Current medicinal chemistry, 2008, Volume: 15, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab

2008
EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Head and Neck Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Signal Transduction

2008
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
    TheScientificWorldJournal, 2008, Sep-21, Volume: 8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines

2008
Clinical pharmacokinetics of tyrosine kinase inhibitors.
    Cancer treatment reviews, 2009, Volume: 35, Issue:8

    Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution

2009
Small-molecule inhibitors of the human epidermal receptor family.
    Expert opinion on investigational drugs, 2009, Volume: 18, Issue:12

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Models, Biological; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2009
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
    Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction

2011
Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
    Current opinion in oncology, 2011, Volume: 23, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Quinazolines

2011
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
    Clinical pharmacokinetics, 2011, Volume: 50, Issue:6

    Topics: Animals; Antineoplastic Agents; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution

2011
Docetaxel combined with targeted therapies in metastatic breast cancer.
    Cancer treatment reviews, 2012, Volume: 38, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Indoles; Lapatinib; Pyrroles; Quinazolines; Sunitinib; Taxoids; Trastuzumab

2012
The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.
    Journal of the American Academy of Dermatology, 2012, Volume: 67, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Incidence; Lapatinib; Nail Diseases; Nails; Panitumumab; Quinazolines; Risk Factors

2012
Role of chemotherapy on brain metastasis.
    Progress in neurological surgery, 2012, Volume: 25

    Topics: Brain Neoplasms; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines

2012
Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.
    Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2012, Volume: 18, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Delivery Systems; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Trastuzumab

2012
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
    Biomaterials, 2013, Volume: 34, Issue:34

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines

2013
Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.
    Chinese journal of cancer, 2014, Volume: 33, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Benzylisoquinolines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Imidazoles; Lapatinib; Multidrug Resistance-Associated Proteins; Piperazines; Purines; Pyrimidines; Quinazolines; Sildenafil Citrate; Sulfonamides; Sulfones; Taxoids; Triazines; Vardenafil Dihydrochloride

2014
Renal toxicity of anticancer agents targeting HER2 and EGFR.
    Journal of nephrology, 2015, Volume: 28, Issue:6

    Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab

2015
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    American journal of clinical oncology, 2016, Volume: 39, Issue:4

    Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus

2016
[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].
    Bulletin du cancer, 2016, Volume: 103, Issue:5

    Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Maternal Age; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk

2016
Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies.
    JNCI cancer spectrum, 2021, Volume: 5, Issue:4

    Topics: Bevacizumab; Brain Neoplasms; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Neoplasms; Outcome Assessment, Health Care; Panitumumab; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic

2021
[Radiation therapy and targeted therapies: Risks and opportunities].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2022, Volume: 26, Issue:6-7

    Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Cetuximab; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiotherapy; Receptor Protein-Tyrosine Kinases; Trastuzumab

2022

Trials

3 trial(s) available for erlotinib hydrochloride and lapatinib

ArticleYear
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
    Oral oncology, 2009, Volume: 45, Issue:10

    Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome

2009
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
    Cancer discovery, 2013, Volume: 3, Issue:5

    Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays

2013
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-20, Volume: 33, Issue:9

    Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult

2015

Other Studies

67 other study(ies) available for erlotinib hydrochloride and lapatinib

ArticleYear
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
    Cancer research, 2004, Sep-15, Volume: 64, Issue:18

    Topics: Amino Acid Sequence; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kinetics; Lapatinib; Models, Molecular; Molecular Sequence Data; Oncogene Proteins v-erbB; Protein Conformation; Protein Structure, Secondary; Quinazolines; Substrate Specificity

2004
Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.
    The Biochemical journal, 2008, Oct-15, Volume: 415, Issue:2

    Topics: Animals; Cell Line; Cell Proliferation; Cell Survival; Drug Combinations; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Immunoblotting; Immunoprecipitation; Interleukin-3; Lapatinib; Mice; Morpholines; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2

2008
Promising newer molecular-targeted therapies in head and neck cancer.
    Drugs, 2008, Volume: 68, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Models, Biological; Niacinamide; Panitumumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2008
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
    Cancer research, 2008, Dec-01, Volume: 68, Issue:23

    Topics: Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Insulin-Like Growth Factor I; Lapatinib; Leptin; Neoplasm Invasiveness; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Receptors, Leptin; Signal Transduction; Transcriptional Activation

2008
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
    Investigational new drugs, 2010, Volume: 28, Issue:4

    Topics: Adenosine Triphosphatases; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Taxoids

2010
In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.
    Biochemistry, 2009, Jul-21, Volume: 48, Issue:28

    Topics: Amino Acid Sequence; Cell Line; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kinetics; Lapatinib; Molecular Sequence Data; Mutant Proteins; Phosphopeptides; Phosphorylation; Phosphotyrosine; Quinazolines; Time Factors

2009
Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.
    Biochemical pharmacology, 2010, Jan-15, Volume: 79, Issue:2

    Topics: Antineoplastic Agents; Blotting, Western; Cell Line; Drug Resistance, Multiple; Erlotinib Hydrochloride; Humans; Lapatinib; Multidrug Resistance-Associated Proteins; Quinazolines

2010
Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
    American journal of respiratory and critical care medicine, 2010, Jan-15, Volume: 181, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Hypertension, Pulmonary; Lapatinib; Male; Mice; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pulmonary Wedge Pressure; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Resistance

2010
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.
    Breast cancer research : BCR, 2009, Volume: 11 Suppl 3

    Topics: Animals; Breast Neoplasms; Drug Discovery; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Technology, Pharmaceutical

2009
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-01, Volume: 16, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoprecipitation; In Situ Hybridization, Fluorescence; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays

2010
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays

2010
Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Sep-01, Volume: 16, Issue:17

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrophy; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Immunohistochemistry; Keratin-16; Lapatinib; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin; Young Adult

2010
Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:3

    Topics: Anilides; Antibodies, Monoclonal; Apoptosis; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Immunoprecipitation; Lapatinib; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor, ErbB-2; Receptors, Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction

2011
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
    Oncology reports, 2011, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat

2011
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
    The Journal of biological chemistry, 2011, Apr-01, Volume: 286, Issue:13

    Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Fluorescence Resonance Energy Transfer; Humans; Lapatinib; Mice; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptors, Fibroblast Growth Factor

2011
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    JOP : Journal of the pancreas, 2011, Mar-09, Volume: 12, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome

2011
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
    Breast cancer research : BCR, 2011, Apr-15, Volume: 13, Issue:2

    Topics: Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Signal Transduction; Staining and Labeling; Treatment Outcome

2011
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
    International journal of cancer, 2012, Jul-01, Volume: 131, Issue:1

    Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab

2012
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
    Journal of the National Cancer Institute. Monographs, 2011, Volume: 2011, Issue:43

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles

2011
[Renal tolerance of targeted therapies].
    Bulletin du cancer, 2012, Mar-01, Volume: 99, Issue:3

    Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib

2012
Treatment of vestibular schwannoma cells with ErbB inhibitors.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2012, Volume: 33, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Ear Neoplasms; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Lapatinib; Neuroma, Acoustic; Oncogene Proteins v-erbB; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Vestibular Nerve

2012
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2012
The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
    International journal of oncology, 2012, Volume: 41, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salivary Gland Neoplasms; Side-Population Cells

2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
    Cancer discovery, 2012, Volume: 2, Issue:5

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lapatinib; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines

2012
Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
    Molecular bioSystems, 2012, Volume: 8, Issue:10

    Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Support Vector Machine

2012
Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
    Molecular oncology, 2012, Volume: 6, Issue:5

    Topics: ADAM Proteins; ADAM17 Protein; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cetuximab; Doxorubicin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Ovarian Neoplasms; Ovary; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Signal Transduction; Trastuzumab

2012
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
    Oncotarget, 2012, Volume: 3, Issue:12

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Oligonucleotide Array Sequence Analysis; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; RNA Interference; Small Ubiquitin-Related Modifier Proteins; Time Factors; Transfection; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays

2012
Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:5

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Y-Box-Binding Protein 1

2013
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, May-01, Volume: 926

    Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles

2013
Predicting drug responsiveness in human cancers using genetically engineered mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-01, Volume: 19, Issue:17

    Topics: Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Oligonucleotide Array Sequence Analysis; Paclitaxel; Quinazolines; Tumor Microenvironment

2013
Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.
    The Journal of biological chemistry, 2013, Oct-18, Volume: 288, Issue:42

    Topics: Animals; CHO Cells; Cricetinae; Cricetulus; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Luciferases; Multienzyme Complexes; Neuregulin-1; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3

2013
EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
    Molecular cancer research : MCR, 2013, Volume: 11, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Cytokines; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inflammation; Lapatinib; NADPH Oxidase 4; NADPH Oxidases; Oligonucleotide Array Sequence Analysis; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Time Factors

2013
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
    Breast cancer research : BCR, 2013, Nov-12, Volume: 15, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2013
EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship.
    Experimental dermatology, 2014, Volume: 23, Issue:1

    Topics: Animals; Animals, Newborn; Cells, Cultured; Desmoglein 1; Desmoglein 3; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Humans; Keratinocytes; Lapatinib; Mice; Mice, Inbred C57BL; Mice, Knockout; Nonlinear Dynamics; Pemphigus; Quinazolines

2014
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:4

    Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African

2014
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
    Acta pharmaceutica Hungarica, 2013, Volume: 83, Issue:4

    Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines

2013
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
    British journal of pharmacology, 2014, Volume: 171, Issue:24

    Topics: AIDS Dementia Complex; Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 5; Dasatinib; Erlotinib Hydrochloride; Flavonoids; HIV Envelope Protein gp120; In Vitro Techniques; Indoles; Lapatinib; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Rats; Roscovitine; Sunitinib; Thiazoles

2014
Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2014, Volume: 22, Issue:12

    Topics: Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Genetic Vectors; Humans; Lapatinib; Lentivirus; Molecular Targeted Therapy; Mutagenesis, Insertional; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Quinazolines

2014
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:12

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression; Glioblastoma; Humans; Lapatinib; Mice; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays

2014
Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.
    Science signaling, 2014, Dec-09, Volume: 7, Issue:355

    Topics: Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Connective Tissue Growth Factor; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hippo Signaling Pathway; Humans; Lapatinib; Mechanotransduction, Cellular; Neuregulin-1; Nuclear Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-4; Transcription Factors

2014
Kinomic profiling of electromagnetic navigational bronchoscopy specimens: a new approach for personalized medicine.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Aged; Aged, 80 and over; Bronchoscopy; Crizotinib; Electromagnetic Phenomena; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Phosphotransferases; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines

2014
Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
    Toxicology and applied pharmacology, 2015, Aug-15, Volume: 287, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Lung Neoplasms; Macrolides; Membrane Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA Interference; Transfection; Vacuolar Proton-Translocating ATPases

2015
EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy.
    Oncotarget, 2015, Jul-10, Volume: 6, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Caspase 8; Cell Line, Tumor; DNA Damage; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoprecipitation; Lapatinib; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Transfection

2015
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
    Amino acids, 2016, Volume: 48, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine

2016
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.
    BMJ open, 2016, Jan-27, Volume: 6, Issue:1

    Topics: Antineoplastic Agents; Commerce; Drug Industry; Erlotinib Hydrochloride; Global Health; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sorafenib

2016
Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR.
    Chembiochem : a European journal of chemical biology, 2016, 06-02, Volume: 17, Issue:11

    Topics: Binding Sites; ErbB Receptors; Erlotinib Hydrochloride; Lapatinib; Ligands; Mutagenesis, Site-Directed; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Spectrometry, Fluorescence

2016
Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors.
    Scientific reports, 2016, 06-08, Volume: 6

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dioxins; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrazoles; Quantitative Structure-Activity Relationship; Quinazolines; Receptor, ErbB-2; Thiourea

2016
JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies.
    Cancer research, 2016, 09-15, Volume: 76, Issue:18

    Topics: Cell Line, Tumor; Computer Simulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Least-Squares Analysis; Linear Models; MAP Kinase Signaling System; Quinazolines; Receptor, ErbB-2

2016
Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Sep-01, Volume: 73, Issue:17

    Topics: Administration, Oral; Chemistry, Pharmaceutical; Dosage Forms; Drug Stability; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Lapatinib; Quinazolines; Suspensions

2016
A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.
    Oncotarget, 2016, Sep-27, Volume: 7, Issue:39

    Topics: Adenovirus E1A Proteins; Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, SCID; Neoplasm Transplantation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases

2016
A Simple High-Performance Liquid Chromatography for Determining Lapatinib and Erlotinib in Human Plasma.
    Therapeutic drug monitoring, 2016, Volume: 38, Issue:6

    Topics: Acetonitriles; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Humans; Lapatinib; Plasma; Quinazolines; Reproducibility of Results; Spectrophotometry, Ultraviolet

2016
Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
    Biochemistry, 2017, Jan-10, Volume: 56, Issue:1

    Topics: Allosteric Regulation; Amino Acid Motifs; Animals; Catalytic Domain; CHO Cells; Cricetinae; Cricetulus; Drug Resistance; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrophobic and Hydrophilic Interactions; Immunoblotting; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines

2017
UPLC-ESI-MS/MS study of the effect of green tea extract on the oral bioavailability of erlotinib and lapatinib in rats: Potential risk of pharmacokinetic interaction.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2017, Apr-01, Volume: 1049-1050

    Topics: Administration, Oral; Animals; Biological Availability; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Herb-Drug Interactions; Lapatinib; Limit of Detection; Linear Models; Plant Extracts; Quinazolines; Rats; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tea

2017
The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:10

    Topics: Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab

2017
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
    Nature communications, 2017, 10-24, Volume: 8, Issue:1

    Topics: Alternative Splicing; Antineoplastic Agents; Benzimidazoles; Biomarkers; Breast Neoplasms; Carrier Proteins; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Genome, Human; Humans; Integrin beta Chains; Lapatinib; Neoplasms; Paclitaxel; Pharmacogenetics; Protein Isoforms; Quinazolines; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Transcriptome

2017
Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.
    Urology, 2018, Volume: 112

    Topics: Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms

2018
NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
    Oxidative medicine and cellular longevity, 2017, Volume: 2017

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; MCF-7 Cells; NF-E2-Related Factor 2; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Tetrahydronaphthalenes

2017
Allosteric regulation of epidermal growth factor (EGF) receptor ligand binding by tyrosine kinase inhibitors.
    The Journal of biological chemistry, 2018, 08-31, Volume: 293, Issue:35

    Topics: Allosteric Regulation; Animals; CHO Cells; Cricetulus; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Protein Binding; Protein Domains; Protein Kinase Inhibitors; Protein Multimerization

2018
Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.
    The oncologist, 2018, Volume: 23, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Sunitinib

2018
Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
    Cutaneous and ocular toxicology, 2019, Volume: 38, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Panitumumab; Pruritus; Retrospective Studies

2019
Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.
    Cell systems, 2019, 05-22, Volume: 8, Issue:5

    Topics: Acclimatization; Antineoplastic Agents; Cardiotoxicity; Cell Differentiation; Cells, Cultured; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Induced Pluripotent Stem Cells; Lapatinib; Myocytes, Cardiac; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib

2019
Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp.
    Anticancer research, 2019, Volume: 39, Issue:7

    Topics: Antimitotic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Protein Kinase Inhibitors; Vincristine

2019
Assessment of modelling strategies for drug response prediction in cell lines and xenografts.
    Scientific reports, 2020, 02-18, Volume: 10, Issue:1

    Topics: Animals; Biomarkers, Pharmacological; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Imidazoles; Indoles; Lapatinib; Machine Learning; Mice; Neoplasms; Organ Specificity; Paclitaxel; Piperazines; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2020
The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.
    Pharmacological reports : PR, 2022, Volume: 74, Issue:5

    Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Triple Negative Breast Neoplasms

2022
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
    International journal of molecular sciences, 2022, Sep-21, Volume: 23, Issue:19

    Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen

2022
Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer.
    BMC bioinformatics, 2022, Oct-19, Volume: 23, Issue:1

    Topics: Adenosine; Afatinib; Crizotinib; Dasatinib; Drug Resistance; Erlotinib Hydrochloride; Etoposide; Humans; Lapatinib; Lung Neoplasms; Tumor Microenvironment; Ubiquitin-Protein Ligases

2022
Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma.
    Pathology oncology research : POR, 2022, Volume: 28

    Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Liver Neoplasms; Oxidative Stress; Prognosis; RNA, Long Noncoding; Sorafenib

2022